The addition of SHBG to the panel of tests in MS or DM2 patients could be beneficial not only by assessing the risk of MS or DM2 itself, but also in combination with sex hormone assessment, allows for a more detailed evaluation of the endocrine system and the resolution of significant disorders from the reproductive system associated with metabolic disorders. This evidence concerns the gene SHBG and myeloid sarcoma.